Virtu Financial LLC Invests $289,000 in Delcath Systems, Inc. (NASDAQ:DCTH)

Virtu Financial LLC purchased a new stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 32,000 shares of the company’s stock, valued at approximately $289,000. Virtu Financial LLC owned approximately 0.10% of Delcath Systems at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the company. AIGH Capital Management LLC raised its position in shares of Delcath Systems by 1.7% in the 2nd quarter. AIGH Capital Management LLC now owns 2,399,792 shares of the company’s stock valued at $20,086,000 after purchasing an additional 40,064 shares in the last quarter. Geode Capital Management LLC boosted its stake in Delcath Systems by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 251,895 shares of the company’s stock valued at $2,275,000 after acquiring an additional 7,298 shares during the last quarter. Polar Asset Management Partners Inc. bought a new position in Delcath Systems during the 3rd quarter valued at $1,594,000. Shellback Capital LP acquired a new position in Delcath Systems during the 2nd quarter worth $1,353,000. Finally, Legato Capital Management LLC bought a new stake in shares of Delcath Systems in the 2nd quarter worth about $966,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Trading Down 2.3 %

Shares of Delcath Systems stock opened at $11.94 on Wednesday. Delcath Systems, Inc. has a twelve month low of $3.12 and a twelve month high of $13.30. The stock has a market capitalization of $381.77 million, a price-to-earnings ratio of -8.84 and a beta of 0.85. The business’s 50 day simple moving average is $10.62 and its 200-day simple moving average is $9.20.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on DCTH shares. Stephens reiterated a “buy” rating on shares of Delcath Systems in a research note on Friday, October 18th. StockNews.com upgraded Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. HC Wainwright reissued a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a research report on Monday, November 11th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Delcath Systems in a report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Delcath Systems has a consensus rating of “Moderate Buy” and a consensus price target of $21.50.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.